Aerie Pharmaceuticals Stock News

Charles Schwab Investment Management Inc. grew its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 3.1% during the fourth quarter, according to its most recent filing with the Securities

Piper sees trial disruption risk, calls out Moderna, Inovio as 'COVID-19 plays' MRNA INO OPK GILD REGN BIIB AMGN DCPH RIGL MNTA QURE FGEN BPMC DBVT BMRN TBPH IMMU ZGNX RMTI MOR VRTX AERI ACAD GBT XLRN

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Bi

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma

Aerie Pharmaceuticals Inc (NASDAQ:AERI) hit a new 52-week low on Friday . The company traded as low as $15.93 and last traded at $16.07, with a volume of 6588 shares. The stock had previously closed a

Friday morning, 940 companies set new 52-week lows. Interesting Points: The largest company by market cap to set a new 52-week low was Bank of America (NYSE: BAC). The...

Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $54.00. The company's shares closed